title: Predictors of pneumonia severity in HIV-infected adults admitted to an Urban public hospital.
abstract: Data on outcomes of community-acquired pneumonia (CAP) in the HIV-infected population are mixed and the perception of worse outcomes in HIV may lead to excess hospitalization. We retrospectively evaluated the utility of the Pneumonia Severity Index, or PORT score, as a prediction rule for mortality in 102 HIV-infected adults hospitalized at an urban public hospital with CAP. Primary outcome was survival at 30 days. Secondary outcomes included survival on discharge, intensive care unit (ICU) admission, length of stay, and readmission within 30 days. The cohort was predominantly male (70%) with a mean age of 45.4 years (standard deviation [SD] ± 7.4). Mean CD4 cell count was 318 cells per microliter; 40 (39%) had CD4 less than 200 cells per microliter. Forty-three percent were on antiretroviral therapy at the time of admission and 31% on prophylactic antibiotics. Twelve patients had bacteremia on admission, predominantly with Streptococcus pneumoniae. Of the 46 patients with admission sputum cultures, 20 yielded an organism, most commonly Haemophilus influenzae and S. pneumoniae. Overall survival in the cohort was high, 96%. Most patients (81%) had a low PORT risk score (class I-III). PORT score predicted 30-day survival (p=0.01) and ICU admission (p=0.03), but antiretroviral use did not. In contrast to a prior study, we did not find that CD4 cell count predicted CAP outcome. Lack of stable housing was not associated with worse outcomes. The PORT score may be a valid tool to predict mortality and need for hospital admission in HIV-infected patients with CAP.
authors.affiliation: Division of Infectious Diseases, Department of Medicine, David Geffen School of Medicine at the University of California, Los Angeles, California 90095, USA. kchew@mednet.ucla.edu
authors.forename: Kara W
authors.initials: KW
authors.lastname: Chew
authors.forename: Irene H
authors.initials: IH
authors.lastname: Yen
authors.forename: Jonathan Z
authors.initials: JZ
authors.lastname: Li
authors.forename: Lisa G
authors.initials: LG
authors.lastname: Winston
mesh_terms: D000328:Adult; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D016470:Bacteremia / Q000150:complications; D017714:Community-Acquired Infections / Q000145:classification / Q000150:complications / Q000188:drug therapy / Q000382:microbiology / Q000401:mortality*; D005260:Female; D015658:HIV Infections / Q000150:complications*; D017052:Hospital Mortality; D006760:Hospitalization / Q000706:statistics & numerical data; D006779:Hospitals, Public; D006786:Hospitals, Urban; D006801:Humans; D008297:Male; D008875:Middle Aged; D011014:Pneumonia / Q000145:classification / Q000150:complications / Q000188:drug therapy / Q000382:microbiology / Q000401:mortality*; D011237:Predictive Value of Tests; D012189:Retrospective Studies; D012307:Risk Factors; D012495:San Francisco / Q000453:epidemiology; D012720:Severity of Illness Index; D016019:Survival Analysis; D016896:Treatment Outcome
chemical_list: D000900:Anti-Bacterial Agents